Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

Purpose Long-term clinical outcome data have established imatinib 400 mg/d as standard
front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML) …

Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have …

For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia.
The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment …

Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for
chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML …

Imatinib mesylate is considered standard of care for first-line treatment of chronic phase
chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International …

Background Imatinib (400 mg daily) is considered the best initial therapy for patients with
newly diagnosed chronic myeloid leukemia (CML) in the chronic phase. However, only a …

Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents a
BCR-ABL protein from exerting its role in the oncogenic pathway in chronic myeloid …

Purpose Imatinib is remarkably effective in treating newly diagnosed patients with chronic
myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come …